Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.061 AUD | +1.67% | +1.67% | +38.64% |
Apr. 03 | Acrux, TruPharma Launch Dapsone 5% Gel in US | MT |
Feb. 29 | Transcript : Acrux Limited, H1 2024 Earnings Call, Feb 29, 2024 |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 5 | 100.0 % | 12 | 100.0 % | +133.74% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe and Other Countries
61.1
%
| 1 | 27.8 % | 7 | 61.1 % | +412.74% |
Australia
29.3
%
| 3 | 66.3 % | 3 | 29.3 % | +3.43% |
United States
9.6
%
| 0 | 5.9 % | 1 | 9.6 % | +282.27% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Kotsanis
CEO | Chief Executive Officer | - | 14-11-02 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21-06-20 |
Chief Tech/Sci/R&D Officer | - | 15-02-14 | |
Mark Hyman
PRN | Corporate Officer/Principal | - | 20-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Geoff Brooke
BRD | Director/Board Member | 68 | 16-05-31 |
Ross Dobinson
FOU | Founder | 72 | 97-12-31 |
Michael Kotsanis
CEO | Chief Executive Officer | - | 14-11-02 |
Timothy Oldham
BRD | Director/Board Member | - | 13-09-30 |
Donald Brumley
BRD | Director/Board Member | - | 21-06-03 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 289,630,985 | 238,390,258 ( 82.31 %) | 0 | 82.31 % |
Company contact information
Sector
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+38.64% | 11.38M | |
+20.85% | 43.34B | |
+20.44% | 21.96B | |
+11.60% | 14.09B | |
+13.21% | 13.64B | |
+39.15% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B |
- Stock Market
- Equities
- ACR Stock
- Company Acrux Limited